Trial Profile
A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Ocriplasmin (Primary)
- Indications Eye disorders; Retinal disorders
- Focus Therapeutic Use
- Acronyms OASIS
- Sponsors Oxurion; ThromboGenics
- 01 Jul 2023 Results (n=72) assessing Resolution of outer retinal abnormalities in eyes with vitreomacular traction without macular hole published in the British Journal of Ophthalmology
- 16 Aug 2017 Results from this trial were presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), according to a ThromboGenics media release.
- 02 Nov 2016 Long-term efficacy results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.